Impact of Baseline SARS-CoV-2 Load in Plasma and Upper Airways on the Incidence of Acute Extrapulmonary Complications of COVID-19: A Multicentric, Prospective, Cohort Study
2024

Impact of SARS-CoV-2 Load on COVID-19 Complications

Sample size: 2625 publication 10 minutes Evidence: high

Author Information

Author(s): Tomas O. Jensen, Katrina Harper, Shaili Gupta, Sean T. Liu, Nila J. Dharan, Jason V. Baker, Sarah L. Pett, Kathryn Shaw-Saliba, Aliasgar Esmail, Minh Q. Ho, Eyad Almasri, Robin L. Dewar, Jens Lundgren, David M. Vock

Primary Institution: Rigshospitalet, University of Copenhagen

Hypothesis

How does the baseline SARS-CoV-2 load in plasma and upper airways affect the incidence of acute extrapulmonary complications in COVID-19 patients?

Conclusion

Higher levels of SARS-CoV-2 in the body are linked to more complications and higher mortality in COVID-19 patients.

Supporting Evidence

  • 20.5% of participants experienced at least one extrapulmonary complication.
  • Higher plasma nucleocapsid antigen levels were associated with increased risk of complications.
  • Extrapulmonary complications were linked to a higher 90-day mortality rate.
  • Patients with high viral loads had a significantly increased risk of complications.
  • Trial treatment allocation did not affect the risk of extrapulmonary complications.

Takeaway

This study found that patients with higher amounts of the virus in their blood and airways are more likely to have serious health problems and die from COVID-19.

Methodology

This was a prospective cohort study involving patients hospitalized for COVID-19 across 114 international sites, analyzing the relationship between viral load and extrapulmonary complications.

Potential Biases

Potential confounding factors related to treatment allocation and vaccination status.

Limitations

The study population was predominantly unvaccinated and enrolled before the emergence of the Omicron variant.

Participant Demographics

Median age was 57 years, 57.7% were male, and 82.9% had at least one comorbid condition.

Statistical Information

P-Value

p<0.001

Confidence Interval

95% CI: 7.3–12.7

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1093/cid/ciae469

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication